Risk factors

What each company says could go wrong in its 10-K, and what changed since last year: the risks added, dropped and rewritten.

7,679 annual reports · 4,010 companies

Readings are automated and can be wrong; check the filing for the exact wording.

Older filings

Page 612 of 640 · 7,679 filings

  • Ares Capital (ARCC) FY2024 10-K risk factors
    59 risks

    Private middle-market lending exposes ARCC to borrower defaults, leverage, subordination, illiquidity, and valuation uncertainty.

    Filed Feb 05, 2025
  • Chipotle Mexican Grill (CMG) FY2024 10-K risk factors
    25 risks

    Chipotle faces heavy risks centered on food safety, supply chain limits for key ingredients like beef and avocados, and rising labor costs tied to minimum wage mandates.

    Filed Feb 05, 2025
  • Ensign Group (ENSG) FY2024 10-K risk factors
    49 risks

    Medicare revenue represents 24.9% of service revenue in 2024. California, Arizona, and Texas account for the majority of total revenue. Geographic and regulatory concentrations dominate the risk profile.

    Filed Feb 05, 2025
  • Hexcel (HXL) FY2024 10-K risk factors
    22 risks

    Airbus and Boeing concentration represents a major commercial aerospace risk. Raw material price and supply availability drive operational profitability. International operations and complex regulatory requirements introduce substantial compliance costs.

    Filed Feb 05, 2025
  • Mondelez International (MDLZ) FY2024 10-K risk factors
    25 risks

    International footprint drives significant exposure to currency fluctuations, global trade policies, and geopolitical conflicts like the war in Ukraine. Input cost volatility in commodities such as cocoa, dairy, and sugar heavily impacts profit margins. Retailer consolidation increases pricing pressure and competition against private label brands.

    Filed Feb 05, 2025
  • Omnicom Group (OMC) FY2024 10-K risk factors
    28 risks

    Omnicom faces significant concentration and macroeconomic exposure, with top clients and international markets driving revenue.

    Filed Feb 05, 2025
  • Regeneron Pharmaceuticals (REGN) FY2024 10-K risk factors
    44 risks

    Regeneron's risk profile is dominated by heavy revenue concentration in EYLEA, EYLEA HD, and Dupixent.

    Filed Feb 05, 2025
  • Reynolds Consumer Products (REYN) FY2024 10-K risk factors
    46 risks

    Reynolds Consumer Products faces heavy operational risks from single-plant dependencies, raw material price volatility, and high debt leverage. Major customer concentration and labor shortages directly threaten profitability and pricing power.

    Filed Feb 05, 2025
  • TEVA Pharmaceutical Industries (TEVA) FY2024 10-K risk factors
    46 risks

    Teva generates significant revenue from generic medicines representing 57.2% of total sales in 2024. Debt stands at $17,783 million requiring substantial interest and principal payments. The company faces heavy competition and patent expirations for innovative drugs like TREANDA.

    Filed Feb 05, 2025
  • Terreno Realty (TRNO) FY2024 10-K risk factors
    52 risks

    Growth relies heavily on industrial property acquisitions and financing availability in target markets. Debt obligations total 823.4 million dollars with credit facility borrowings. Strict REIT compliance is required to avoid taxation penalties.

    Filed Feb 05, 2025
  • Baker Hughes (BKR) FY2024 10-K risk factors
    45 risks

    The risk factors are dominated by energy transition pressures, customer credit risk in Mexico, GE supplier dependency, and geopolitical conflicts.

    Filed Feb 04, 2025
  • Healthpeak Properties (DOC) FY2024 10-K risk factors
    58 risks

    Healthpeak faces significant risks from healthcare property sector concentration, tenant financial health, and rising interest rates.

    Filed Feb 04, 2025

Companies covered

4,010 companies

371 more under A